Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Short-term Investments: 2021-2024

Historic Short-term Investments for Krystal Biotech (KRYS) over the last 4 years, with Dec 2024 value amounting to $252.7 million.

  • Krystal Biotech's Short-term Investments rose 57.90% to $338.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $338.5 million, marking a year-over-year increase of 57.90%. This contributed to the annual value of $252.7 million for FY2024, which is 45.33% up from last year.
  • Latest data reveals that Krystal Biotech reported Short-term Investments of $252.7 million as of FY2024, which was up 45.33% from $173.8 million recorded in FY2023.
  • In the past 5 years, Krystal Biotech's Short-term Investments registered a high of $252.7 million during FY2024, and its lowest value of $96.8 million during FY2021.
  • In the last 3 years, Krystal Biotech's Short-term Investments had a median value of $217.3 million in 2022 and averaged $214.6 million.
  • In the last 5 years, Krystal Biotech's Short-term Investments soared by 124.34% in 2022 and then decreased by 19.98% in 2023.
  • Krystal Biotech's Short-term Investments (Yearly) stood at $96.8 million in 2021, then skyrocketed by 124.34% to $217.3 million in 2022, then decreased by 19.98% to $173.8 million in 2023, then surged by 45.33% to $252.7 million in 2024.